“BioAsia Summit has demonstrated a continuous evolution”

BioAsia, the pioneering annual event dedicated to the lifesciences sector, is all set to host its 21st edition, BioAsia 2024 from February 26 to 28, 2024 in Hyderabad. The event themed “Data and AI: Redefining Possibilities,” is aimed at transforming the future of life sciences.

In an exclusive interview, Jayesh Ranjan, IAS, Principal Secretary, Department of Information Technology, Electronics & Communications (ITE&C) and the Department of Industries & Commerce, Government of Telangana shared his views with Rahul Koul, Chief Editor, BioVoice News. Read the excerpts:

Over the last two decades, BioAsia has emerged as one of the top life sciences industry events. How do you measure its success and broader impact on the sector in India and Asia-Pacific?

BioAsia’s success can be measured through various key metrics. One notable indicator is the consistent growth in participation, both in terms of the number of attendees and the diversity of stakeholders represented. The event’s ability to attract top-tier industry professionals, researchers, and policymakers underscores its significance as a platform for networking and collaboration. This year too we have the most renowned Mr. Dave Ricks, CEO of Eli Lilly, Mr. Geoff Martha, Chairman and CEO of Medtronic, Dr. Chris Boerner, CEO of BMS, Mr. Christophe Weber, CEO of Takeda, and also the Nobel Laureate Prof. Gregg Semenza.

BioAsia has played a pivotal role in positioning India and the Asia-Pacific region as key players in the global life sciences arena, influencing policy, research, and business developments and I strongly believe BioAsia has played a key role in our journey to becoming the life sciences capital of India and an important hub globally. BioAsia has also helped us get recognized at a global level and has connected us to the global ecosystem, which is crucial for us to support our Vision for the Industry.

How does BioAsia contribute to the global dialogue on life sciences while being responsive to emerging needs as well as valuable to a broad spectrum of participants?

Currently, we incorporated a diverse range of participants, spanning academia, industry, government, and investors. This flexibility and inclusiveness significantly contribute to BioAsia’s influential role in the global discourse on life sciences. BioAsia 2024 is poised to enhance this legacy by convening influential leaders and participants from over 50 countries, fostering collaborations beyond geographical boundaries.

“The state of Telangana has been a frontrunner in identifying the importance of life sciences, pharma and of course the development of holistic healthcare.”

What should the participants and other stakeholders expect from BioAsia 2024? 

Our BioAsia Summit has demonstrated a continuous evolution, adapting and advancing with each edition.  Firstly, the upcoming summit is likely to showcase the latest advancements in the life sciences industry, with a particular focus on the theme, “Data and AI: Redefining Possibilities.” This suggests a deep exploration of how the convergence of human ingenuity and artificial intelligence is reshaping various facets of healthcare, including research, diagnostics, treatment methodologies, and patient care.

Secondly, the summit will provide a platform for networking and collaboration, bringing together thought leaders, professionals, and experts from around the world. Attendees can anticipate engaging discussions, interactive panel sessions, and workshops that delve into the current state and future trajectory of the biotechnology and healthcare sectors. The summit also features an exhibition where companies and organizations showcase their innovations and technologies, offering participants a firsthand look at the latest developments in the field.

Given the thematic focus on data and AI, BioAsia 2024 is expected to highlight how these technologies are driving transformative changes in the industry. Participants can gain valuable insights into the challenges and opportunities presented by this technological convergence and explore ways to harness its potential for advancements in healthcare and biotechnology.

In which ways would the 21st edition of BioAsia be different from previous ones?

The 21st edition of BioAsia will distinguish itself from its predecessors by placing a spotlight on the theme “Data and AI: Redefining Possibilities.” This thematic focus suggests a concentrated exploration of the transformative impact of data and artificial intelligence on various facets of the life sciences industry, including research, diagnostics, treatment methodologies, and patient care. The conference is likely to feature a specialized lineup of speakers and thought leaders at the forefront of the data and AI revolution, introducing cutting-edge technologies and innovations in these domains. The 21st edition will also offer enhanced networking opportunities and a more global perspective, fostering collaboration and discussions on the evolving landscape of healthcare and biotechnology

What are the significant trends shaping the future of life sciences sector in Telangana? Could you throw light on a few major ongoing and upcoming initiatives?

India has emerged as a global pharmaceutical powerhouse, earning the moniker “pharmacy of the world.”. Telangana envisions significant opportunities in various segments, including complex generics, specialty pharma, biosimilars, novel biological drugs, and cutting-edge technologies such as CAR-T and other cell and gene therapies, mRNA, vaccines, and preventives. The state aims to transcend its role as a pill supplier and establish itself as a global innovation hub, addressing unmet needs in the life sciences sector.

The state of Telangana has been a frontrunner in identifying the importance of life sciences, pharma and of course the development of holistic healthcare. This state-of-the-art infrastructure, combined with progressive policies and proactive execution on the part of the government, has not only distinguished Telangana as a progressive state, but also enhanced our share and contribution to positive health outcome nationally and globally.

*BioVoice News is one of the leading media partners of BioAsia 2024.